SG/CALL/BRISTOL-MYERS SQUIBB/70/0.1/17.01.25

SG/CALL/BRISTOL-MYERS SQUIBB/70/0.1/17.01.25 Stock

DE000SQ86UE2

Delayed Deutsche Boerse AG 11:49:38 2024-06-03 am EDT
0.007 ^EUR	+16.67%

1 month	-45.45%
3 months	-86.36%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart BRISTOL-MYERS SQUIBB COMPANY

Chart SG/CALL/BRISTOL-MYERS SQUIBB/70/0.1/17.01.25

Latest news about BRISTOL-MYERS SQUIBB COMPANY

Bristol Myers Squibb’s Breyanzi Demonstrates Clinically Meaningful Outcomes Across Broad Range of B-Cell Malignancies in New Data Presented at 2024 ASCO® Annual Meeting	10:14am	BU
Bristol Myers: presents advances in lung cancer	08:58am	CF
Bristol Myers Squibb Presents Multiple New Analyses at 2024 ASCO® Annual Meeting Highlighting Opdivo and Opdivo-based Combinations in Early and Advanced Stages of Non-Small Cell Lung Cancer	08:09am	BU
Pre-surgery treatment with Bristol Myers combination therapy leads to better skin cancer outcomes	Jun. 02	RE

More news

Quotes 5-day view

Date	Price	Change
24-06-03	0.007	+16.67%
24-05-31	0.006	+20.00%
24-05-30	0.005	0.00%
24-05-29	0.005	0.00%
24-05-28	0.005	-50.00%

Delayed Quote Deutsche Boerse AG

Last update June 03, 2024 at 11:49 am EDT

More quotes

Static data

Product type	Plain-Vanilla-Warrants
Buy / Sell	CALL
Underlying	BRISTOL-MYERS SQUIBB COMPANY
Issuer	Société Générale
WKN	SQ86UE
ISIN	DE000SQ86UE2
Date issued	2023-02-16
Strike	70 $
Maturity	2025-01-17 (228 Days)
Parity	10 : 1
Emission price	1.14 €
Emission volume	N/A
Settlement	cash
Currency	EUR

Technical Indicators

Highest since issue	1.07 €
Lowest since issue	0.004 €
Spread	0.013 €
Spread %	65.00%

Company Profile

Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques. The United States account for 70.1% of net sales.

Sector

More about the company

Ratings for Bristol-Myers Squibb Company

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Consensus: Bristol-Myers Squibb Company

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

41.09 USD

Average target price

53.19 USD

Spread / Average Target

+29.46%

Consensus